ABUS insider trading
Open-market stock trades by Arbutus Biopharma (ABUS) executives and directors: who bought or sold, how many shares, at what price and when.
ABUS insider trades
| Date | Insider | Role | Trade | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Feb 4, 2025 | HASTINGS DAVID C | Chief Financial Officer | Sell | 22,183 | $3.28 | $72.83K |
| Feb 4, 2025 | Sims Karen | Chief Medical Officer | Sell | 19,348 | $3.28 | $63.52K |
| Feb 4, 2025 | McElhaugh Michael J. | Interim President & CEO | Sell | 23,790 | $3.28 | $78.10K |
| Feb 4, 2025 | Naftzger J. Christopher | General Counsel and CCO | Sell | 11,333 | $3.28 | $37.21K |
| Aug 14, 2024 | MANCHESTER KEITH S | director | Sell | 8,846 | $3.69 | $32.64K |
| Feb 2, 2024 | Sims Karen | Chief Medical Officer | Sell | 4,358 | $2.31 | $10.08K |
| Feb 2, 2024 | HASTINGS DAVID C | Chief Financial Officer | Sell | 9,593 | $2.31 | $22.18K |
| Feb 2, 2024 | Sofia Michael J. | Chief Scientific Officer | Sell | 9,982 | $2.31 | $23.08K |
| Feb 2, 2024 | McElhaugh Michael J. | Interim President & CEO | Sell | 10,164 | $2.31 | $23.50K |
- ABUS insiders bought $0.00 and sold $363.14K in open-market trades over their last 9 filings.
Updated 2026-11-03 11:32 UTC